Advanced search×

Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies.

Glen J GJ Weiss, Jeffrey R JR Infante, E Gabriela EG Chiorean, Mitesh J MJ Borad, Johanna C JC Bendell, Julian R JR Molina, Raoul R Tibes, Ramesh K RK Ramanathan, Karen K Lewandowski, Suzanne F SF Jones, Mario E ME Lacouture, Virginia K VK Langmuir, Hank H Lee, Stew S Kroll, and Howard A HA Burris

Clin Cancer Res 17(9):2997-3004 (2011) PMID 21415214

The objectives of this phase 1, first-in-human study were to determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), safety, pharmacokinetics, and preliminary activity of the hypoxia-activated prodrug TH-302 in patients with advanced solid tumors.

DOI: 10.1158/1078-0432.CCR-10-3425
Version: za2963e q8zae q8zb0 q8zc4 q8zd6 q8ze0 q8zf6 q8zg1

Similar articles you may find interesting…

  1. A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcin...
    John D JD Hainsworth, Jeffrey R JR Infante, ... Howard A HA Burris

    Cancer Invest 29(7):451-5 (2011) PMID 21696296

    Twenty patients were treated with no objective responses. All patients progressed or stopped treatment prior to the 16-week reevaluation. Panobinostat was generally well-tolerated. Conclusion: Panobinostat had no activity in this group of patients with refractory renal carcinoma. Further development...
  2. A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced ...
    J R JR Infante, R R Kurzrock, ... R S RS Herbst

    Cancer Chemother Pharmacol 69(1):165-72 (2012) PMID 21638123

    In part A, 29 patients received at least one dose of AZD4877 (5 mg, n = 4; 7.5 mg, n = 4; 10 mg, n = 3; 15 mg, n = 3; 20 mg, n = 3; 30 mg, n = 6; 36 mg, n = 3; 45 mg, n = 3). The MTD was defined as 30 mg, with the primary DLT being neutropenia. Although exposures appeared to...
  3. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
    Shengrong Li, Jinsong Zhang, ... Jian-Xin Duan

    Biol Trace Elem Res 136(3):294-301 (2010) PMID 19838642

    We previously demonstrated that IFO could inhibit tumor TrxR activity and chloro-IPM is known to bind covalently to the seleno-cysteine dipeptide in thioredoxin reductase. The present study assessed the ability of TH-302 to activate in the tumors of mice-bearing hepatoma 22 (H22) and inactivate the...